The effect of moxonidine on endothelial dysfunction in metabolic syndrome

Basit Öğe Kaydı
dc.authorscopusid6603650693
dc.authorscopusid6508070009
dc.authorscopusid6504632247
dc.authorscopusid6602609706
dc.authorscopusid7003301157
dc.contributor.authorTopal E.
dc.contributor.authorCikim A.S.
dc.contributor.authorCikim K.
dc.contributor.authorTemel I.
dc.contributor.authorOzdemir R.
dc.date.accessioned2024-08-04T20:00:49Z
dc.date.available2024-08-04T20:00:49Z
dc.date.issued2006
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Endothelial dysfunction has been reported in patients with type 2 diabetes mellitus and even in healthy obese individuals with a normal metabolic profile. Sympathetic activity commonly is increased in obese hypertensive patients, and moxonidine is effective in lowering BP and improving insulin sensitivity. Objective: To evaluate the effect of moxonidine on endothelial dysfunction in patients with metabolic syndrome. Methods: Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone. Anthropometric (body mass index, waist and hip circumferences, and waist-to-hip ratio) and metabolic features (fasting plasma glucose and insulin, aminotransferases, ?-glutamyl transpeptidase, triglycerides, and cholesterol levels) and flow-mediated dilatation (FMD) were evaluated. Insulin resistance was calculated by using the homeostasis model assessment formula. Insulin sensitivity was calculated according to the quantitative insulin-sensitivity check index (QUICKI). Results: SBP and DBP (both p < 0.001) and waist circumference (p = 0.02) were higher, and QUICKI (p = 0.043) and FMD (p = 0.01) were lower in the hypertensive group at baseline. After 3 months, nearly all the study parameters improved in both treatment groups. The decrease in BP, increase in FMD, and improvements in metabolic and anthropometric parameters were significantly greater in the moxonidine-treated group than in those treated with diet alone. Conclusion: Moxonidine is proposed as a valuable option for treating mild-to-moderate hypertension in obese and insulin-resistant patients with metabolic syndrome as it appears to improve endothelial dysfunction in these patients. © 2006 Adis Data Information BV. All rights reserved.en_US
dc.identifier.doi10.2165/00129784-200606050-00007
dc.identifier.endpage348en_US
dc.identifier.issn1175-3277
dc.identifier.issue5en_US
dc.identifier.pmid17083269en_US
dc.identifier.scopus2-s2.0-33750976654en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage343en_US
dc.identifier.urihttps://doi.org/10.2165/00129784-200606050-00007
dc.identifier.urihttps://hdl.handle.net/11616/91035
dc.identifier.volume6en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofAmerican Journal of Cardiovascular Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectaminotransferaseen_US
dc.subjectcholesterolen_US
dc.subjectgamma glutamyltransferaseen_US
dc.subjectglucoseen_US
dc.subjectinsulinen_US
dc.subjectmoxonidineen_US
dc.subjecttriacylglycerolen_US
dc.subjectadulten_US
dc.subjectaminotransferase blood levelen_US
dc.subjectanthropometryen_US
dc.subjectarticleen_US
dc.subjectbody massen_US
dc.subjectcaloric restrictionen_US
dc.subjectcholesterol blood levelen_US
dc.subjectcontrolled studyen_US
dc.subjectdrug effecten_US
dc.subjectfemaleen_US
dc.subjectgamma glutamyl transferase blood levelen_US
dc.subjectglucose blood levelen_US
dc.subjecthomeostasisen_US
dc.subjecthumanen_US
dc.subjecthypertensionen_US
dc.subjectinsulin blood levelen_US
dc.subjectinsulin resistanceen_US
dc.subjectinsulin sensitivityen_US
dc.subjectlow calory dieten_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmetabolic syndrome Xen_US
dc.subjectpriority journalen_US
dc.subjecttriacylglycerol blood levelen_US
dc.subjectvascular endotheliumen_US
dc.subjectvasodilatationen_US
dc.subjectwaist circumferenceen_US
dc.subjectwaist hip ratioen_US
dc.subjectAdulten_US
dc.subjectAntihypertensive Agentsen_US
dc.subjectBlood Pressure Determinationen_US
dc.subjectCaloric Restrictionen_US
dc.subjectCombined Modality Therapyen_US
dc.subjectEndothelium, Vascularen_US
dc.subjectFemaleen_US
dc.subjectgamma-Glutamyltransferaseen_US
dc.subjectHumansen_US
dc.subjectHypertensionen_US
dc.subjectImidazolesen_US
dc.subjectMaleen_US
dc.subjectMetabolic Syndrome Xen_US
dc.subjectMiddle Ageden_US
dc.subjectObesityen_US
dc.subjectTime Factorsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectWaist-Hip Ratioen_US
dc.titleThe effect of moxonidine on endothelial dysfunction in metabolic syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu